Please login to the form below

Not currently logged in
Email:
Password:

cangrelor

This page shows the latest cangrelor news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

cangrelor. Kengrexal. percutaneous coronary intervention (PCI). P2Y12 inhibitor. The Medicines Company.

Latest news

  • FDA gives the nod to TMC's antiplatelet drug FDA gives the nod to TMC's antiplatelet drug

    Kengreal (cangrelor) has been approved by the FDA for adult patients undergoing percutaneous coronary intervention (PCI) to open a blocked or narrowed coronary artery, three months after being given a green ... TMC's efforts to bring cangrelor to market

  • AZ and Takeda drugs should carry heart failure warning AZ and Takeda drugs should carry heart failure warning

    Cangrelor go-ahead. Meanwhile, the FDA's advisory committee also voted 9 to 2 in favour of approving The Medicines Company's injectable anticoagulant cangrelor as an adjunct to percutaneous coronary ... The FDA is due to deliver a final decision on

  • FDA reviewer backs approval of TMC's cangrelor FDA reviewer backs approval of TMC's cangrelor

    Claims it offers a small benefit over Sanofi’s Plavix.  . The Medicines Company (TMC) looks on course finally to get approval for its intravenous antiplatelet drug cangrelor in the US after ... Analysts had at one point been predicting sales of

  • Antibiotics among 7 new drugs backed by EMA Antibiotics among 7 new drugs backed by EMA

    Kengrexal (cangrelor) was recommended for use in the reduction of thrombotic cardiovascular events in adults with coronary artery disease.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics